Roche to up R&D spend as it realigns operations

Share this article:
Roche announced plans to increase spending on research and development and introduced a new operating model reorganizing its development and marketing efforts. Roche said its R&D spending would rise further than the $4.8 billion it spent in 2006 over the next few years but did not provide exact figures. The drugmaker also announced plans to reorganize its business operations around five disease biology units combining discovery, R&D and marketing. The cancer drugs unit will be housed in Nutley, NJ, Roche said. The virology and inflammation units will be located in Palo Alto, CA and metabolism and central nervous system will be housed at Roche facilities in Basel, Switzerland. “By combing existing expertise in disease biology areas, we will further enhance the optimal conditions for bringing future innovations to fruition faster and more efficiently – with clear benefits for patients and doctors,” CEO Franz Humer said.
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.